RT Journal Article
SR Electronic
T1 Optimal vaccination with time-varying based on immunity barrier in Hunan Province, China
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.03.02.22271610
DO 10.1101/2022.03.02.22271610
A1 Guo, Xiaohao
A1 Liu, Ziyan
A1 Yang, Shiting
A1 Zhao, Zeyu
A1 Guo, Yichao
A1 Abudurusuli, Guzainuer
A1 Rui, Jia
A1 Wang, Yao
A1 Zhao, Shanlu
A1 Zeng, Ge
A1 Hu, Shixiong
A1 Luo, Kaiwei
A1 Chen, Tianmu
YR 2022
UL http://medrxiv.org/content/early/2022/03/03/2022.03.02.22271610.abstract
AB The current outbreak of novel coronavirus disease 2019 (COVID-19) is already causing a serious disease burden worldwide, this paper analyzed data of a delta variant Covid-19 outbreak in Hunan, China, and proposed an optimal dose-wise dynamical vaccinating process based on local contact pattern and vaccine coverage that minimize the accumulative cases in a certain future time interval. The optimized result requires an immediate vaccination to that none vaccinated at age group 30 to 39, which is coherent to the prevailing strategies. The dose-wise optimal vaccinating process can be directive for countries or regions where vaccines are not abundant. We recommend that vaccination should be further intensified to increase the coverage of booster shots, thus effectively reducing the spread of COVID-19.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was funded by the Bill & Melinda Gates Foundation (INV-005834), and the Impact on prevention and control COVID-19 of vaccination intention and effectiveness: a modelling study(2021YFC2301604).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors